Use of bortezomib to overcome the poor prognosis of t(4;14), but not del(17p), in young patients with newly diagnosed multiple myeloma.
Authors:
- H. Avet-LoiseauHAH. Avet-Loiseau
- P. MoreauPMP. Moreau
- C. MathiotCMC. Mathiot
- C. CharbonnelCCC. Charbonnel
- T. FaconTFT. Facon
- M. AttalMAM. Attal
- C. HulinCHC. Hulin
- G. MaritGMG. Marit
- S. MinvielleSMS. Minvielle
- J. HarousseauJHJ. Harousseau
- Intergroupe Francophone du MyãlomeIMIntergroupe Francophone du Myãlome
- 20 May 2010
- journal article
- lymphoma and-plasma-cell-disorders
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15_suppl) , 8113